@article {1632288,
	title = {It is time for a moonshot to find "Cures" for diabetic retinal disease},
	journal = {Prog Retin Eye Res},
	volume = {90},
	year = {2022},
	month = {2022 Sep},
	pages = {101051},
	abstract = {Diabetic retinal disease (DRD), the most common complication of diabetes and a leading cause of blindness in working age individuals, is now understood to be a form of sensory neuropathy or neurovascular degeneration. Current treatments are focused on advanced vision-threatening disease and a single molecular target, vascular endothelial growth factor, has an approved therapy. We trace the evolution of understanding of DRD pathogenesis, identify new approaches to clinical assessment, trials infrastructure and design, and target identification to accelerate selection and evaluation of new therapeutics that will speed development of potentially curative interventions. Critically, the "Restoring Vision Moonshot" framework will address gaps in knowledge to be filled to achieve the goal of restoring sight and preventing vision loss in persons with diabetes.},
	keywords = {Diabetes Mellitus, Diabetic Retinopathy, Humans, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Vision Disorders},
	issn = {1873-1635},
	doi = {10.1016/j.preteyeres.2022.101051},
	author = {Levine, S Robert and Sapieha, Przemyslaw and Dutta, Sanjoy and Sun, Jennifer K and Gardner, Thomas W}
}
